Evidence map›Paper›PMID 28780723›Full record

ArticlePathology oncology research : POR2018

Vitamin D Receptor Gene Polymorphism: Association with Susceptibility to Early-Onset Breast Cancer in Iranian, BRCA1/2-Mutation Carrier and non-carrier Patients.

Ahmad Shahabi, Majid Alipour, Hamid Safiri, Parsa Tavakol, Mehdi Alizadeh, S Milad Hashemi, Mahdieh Shahabi, Mohammad Halimi

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. The Potential Role of Vitamin D inInternational journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Vitamin D and Breast Cancer: Latest Evidence and Future Steps.Breast cancer : basic and clinical research · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Ahmad ShahabiDepartment of Biology, Babol Branch, Islamic Azad University, Babol, Iran.
Majid AlipourDepartment of Biology, Babol Branch, Islamic Azad University, Babol, Iran.
Hamid SafiriShahid Rajayee Hospital, Babol University of Medical Sciences, Babol, Iran.
Parsa TavakolDepartment of Biology, Babol Branch, Islamic Azad University, Babol, Iran.
Mehdi AlizadehDepartment of biology, Faculty of Basic Sciences, Imam Hossein University, Tehran, Iran.
S Milad HashemiDepartment of Biology, Babol Branch, Islamic Azad University, Babol, Iran.
Mahdieh ShahabiBelarusian state medical university, Minsk, Belarus.
Mohammad HalimiDepartment of Biology, Babol Branch, Islamic Azad University, Babol, Iran. halimi@baboliau.ac.ir.
Islamic Azad University, BabolBabol University of Medical Sciences · IRBelarusian State Medical University · BYImam Hossein University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mounting evidences support that vitamin D insufficiency or deficiency is a risk factor of breast cancer. Vitamin D receptor (VDR) is expressed in more than 36 cell types in different organs as in cancerous cells. Numerous allelic variants of VDR gene have been identified in human populations. Association of FokI (rs2228570) and BsmI (rs1544410) single nucleotide polymorphisms (SNPs) in VDR gene with the risk of breast cancer have been investigated in several studies, however, the published data are still inconsistent. Here, we investigated BsmI and FokI polymorphisms in Iranian young (≤ 35 years old) breast cancer patient with known BRCA1/2 germline mutations. VDR gene polymorphisms were detected by restriction fragment length polymorphism (RFLP) analysis in a cohort of 203 breast cancer patients and 214 controls from Iran. There was a significant association between the bb and Bb genotypes of the BsmI and the increased risk of breast cancer (OR 1.74, CI 1.06-2.87 and OR 2.08, CI 1.31-3.29, respectively). This association was maintained in the subgroup of BRCA1/2 mutation non carriers (OR 1.90, CI 1.15-3.20 and OR 1.75, CI 1.07-2.87 for bb and Bb genotypes respectively) and in the subgroup of BRCA1/2 mutation non-carriers with a family history of breast and/or ovarian cancer (OR 1.81, CI 1.08-3.05 and OR 1.65, CI 1.00-2.70 for bb and Bb genotypes respectively). None of the FokI homozygous or heterozygous genotypes were associated with the risk of breast cancer. In summary, the BsmI polymorphism of VDR gene may be associated with the risk of breast cancer in Iranian women.

Indexed as

MutationPolymorphism, Single NucleotideAdultAge of OnsetBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCase-Control StudiesFemaleFollow-Up StudiesGenetic Predisposition to DiseaseGenotypeHeterozygoteHumansIranBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanReceptors, CalcitriolVDR protein, humanBreast cancerPolymorphismVitamin D receptor

Identifiers

PMID28780723
OpenAlexW2743378948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.